Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Targeted therapies for cancer 2004.

Publication ,  Journal Article
Ross, JS; Schenkein, DP; Pietrusko, R; Rolfe, M; Linette, GP; Stec, J; Stagliano, NE; Ginsburg, GS; Symmans, WF; Pusztai, L; Hortobagyi, GN
Published in: Am J Clin Pathol
October 2004

The regulatory agency approvals in the United States and Europe of imatinib mesylate (Gleevec) for patients with bcr/abl-positive chronic myelogenous leukemia, cetuximab (Erbitux) for patients with epidermal growth factor receptor overexpressing metastatic colorectal cancer, the antiangiogenesis agent bevacizumab (Avastin), and the proteasome inhibitor bortezomib (Velcade)--and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment--are driving a new era of integrated diagnostics and therapeutics. The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with non-small cell lung cancer treated with gefitinib (Iressa) has intensified this interest. In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu overexpressing metastatic breast cancer: The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered. This review also considers the widely held view that, in the next 5 to 10 years, the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process; customize the selection, dosing, route of administration of existing and new therapeutic agents; and truly personalize medical care for cancer patients.

Duke Scholars

Published In

Am J Clin Pathol

DOI

ISSN

0002-9173

Publication Date

October 2004

Volume

122

Issue

4

Start / End Page

598 / 609

Location

England

Related Subject Headings

  • Trastuzumab
  • Rituximab
  • Quinazolines
  • Pharmacogenetics
  • Pathology
  • Neoplasms
  • Humans
  • Gemtuzumab
  • Gefitinib
  • Erlotinib Hydrochloride
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ross, J. S., Schenkein, D. P., Pietrusko, R., Rolfe, M., Linette, G. P., Stec, J., … Hortobagyi, G. N. (2004). Targeted therapies for cancer 2004. Am J Clin Pathol, 122(4), 598–609. https://doi.org/10.1309/5CWP-U41A-FR1V-YM3F
Ross, Jeffrey S., David P. Schenkein, Robert Pietrusko, Mark Rolfe, Gerald P. Linette, James Stec, Nancy E. Stagliano, et al. “Targeted therapies for cancer 2004.Am J Clin Pathol 122, no. 4 (October 2004): 598–609. https://doi.org/10.1309/5CWP-U41A-FR1V-YM3F.
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004 Oct;122(4):598–609.
Ross, Jeffrey S., et al. “Targeted therapies for cancer 2004.Am J Clin Pathol, vol. 122, no. 4, Oct. 2004, pp. 598–609. Pubmed, doi:10.1309/5CWP-U41A-FR1V-YM3F.
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004 Oct;122(4):598–609.
Journal cover image

Published In

Am J Clin Pathol

DOI

ISSN

0002-9173

Publication Date

October 2004

Volume

122

Issue

4

Start / End Page

598 / 609

Location

England

Related Subject Headings

  • Trastuzumab
  • Rituximab
  • Quinazolines
  • Pharmacogenetics
  • Pathology
  • Neoplasms
  • Humans
  • Gemtuzumab
  • Gefitinib
  • Erlotinib Hydrochloride